Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph Ciccolini

Showing results (111-120 of 168) with videos related to

Pageof 17
Sort By:
Pharmacogenomics|March 3, 2012
CDA deficiency as a possible culprit for life-threatening toxicities after cytarabine plus 6-mercaptopurine therapy: pharmacogenetic investigationsJoseph Ciccolini, Alexandre Evrard, Lithaty M'Batchi, et al.
Pharmacogenomics|November 12, 2015
Yin and yang of cytidine deaminase roles in clinical response to azacitidine in the elderly: a pharmacogenetics taleRaphaelle Fanciullino, Cédric Mercier, Cindy Serdjebi, et al.
International Journal of Nanomedicine|November 15, 2018
From 3D spheroids to tumor bearing mice: efficacy and distribution studies of trastuzumab-docetaxel immunoliposome in breast cancerAnne Rodallec, Guillaume Sicard, Sarah Giacometti, et al.
CPT: Pharmacometrics & Systems Pharmacology|December 9, 2017
Revisiting Bevacizumab + Cytotoxics Scheduling Using Mathematical Modeling: Proof of Concept Study in Experimental Non-Small Cell Lung CarcinomaDiane-Charlotte Imbs, Raouf El Cheikh, Arnaud Boyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2003
Phase I and pharmacokinetic study of escalating dose of docetaxel administered with granulocyte colony-stimulating factor support in adult advanced solid tumorsAnthony Gonçalves, Frederic Viret, Joseph Ciccolini, et al.
British Journal of Clinical Pharmacology|February 26, 2008
A well-tolerated 5-FU-based treatment subsequent to severe capecitabine-induced toxicity in a DPD-deficient patientHélène Blasco, Michéle Boisdron-Celle, Philippe Bougnoux, et al.
Molecular Cancer Therapeutics|December 17, 2002
Transmission of apoptosis in human colorectal tumor cells exposed to capecitabine, Xeloda, is mediated via FasJoseph Ciccolini, Frédéric Fina, Karine Bezulier, et al.
Oncotarget|October 19, 2011
Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatmentEddy Pasquier, Joseph Ciccolini, Manon Carre, et al.
Plos Computational Biology|February 26, 2020
Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumorsCristina Vaghi, Anne Rodallec, Raphaëlle Fanciullino, et al.
Therapeutic Drug Monitoring|December 17, 2009
High-resolution melting analysis of sequence variations in the cytidine deaminase gene (CDA) in patients with cancer treated with gemcitabineCaroline Raynal, Joseph Ciccolini, Cédric Mercier, et al.
Pageof 17

Showing results (111-120 of 168) with videos related to

Sort By:
Pageof 17
Pharmacogenomics|March 3, 2012
CDA deficiency as a possible culprit for life-threatening toxicities after cytarabine plus 6-mercaptopurine therapy: pharmacogenetic investigationsJoseph Ciccolini, Alexandre Evrard, Lithaty M'Batchi, et al.
Pharmacogenomics|November 12, 2015
Yin and yang of cytidine deaminase roles in clinical response to azacitidine in the elderly: a pharmacogenetics taleRaphaelle Fanciullino, Cédric Mercier, Cindy Serdjebi, et al.
International Journal of Nanomedicine|November 15, 2018
From 3D spheroids to tumor bearing mice: efficacy and distribution studies of trastuzumab-docetaxel immunoliposome in breast cancerAnne Rodallec, Guillaume Sicard, Sarah Giacometti, et al.
CPT: Pharmacometrics & Systems Pharmacology|December 9, 2017
Revisiting Bevacizumab + Cytotoxics Scheduling Using Mathematical Modeling: Proof of Concept Study in Experimental Non-Small Cell Lung CarcinomaDiane-Charlotte Imbs, Raouf El Cheikh, Arnaud Boyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2003
Phase I and pharmacokinetic study of escalating dose of docetaxel administered with granulocyte colony-stimulating factor support in adult advanced solid tumorsAnthony Gonçalves, Frederic Viret, Joseph Ciccolini, et al.
British Journal of Clinical Pharmacology|February 26, 2008
A well-tolerated 5-FU-based treatment subsequent to severe capecitabine-induced toxicity in a DPD-deficient patientHélène Blasco, Michéle Boisdron-Celle, Philippe Bougnoux, et al.
Molecular Cancer Therapeutics|December 17, 2002
Transmission of apoptosis in human colorectal tumor cells exposed to capecitabine, Xeloda, is mediated via FasJoseph Ciccolini, Frédéric Fina, Karine Bezulier, et al.
Oncotarget|October 19, 2011
Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatmentEddy Pasquier, Joseph Ciccolini, Manon Carre, et al.
Plos Computational Biology|February 26, 2020
Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumorsCristina Vaghi, Anne Rodallec, Raphaëlle Fanciullino, et al.
Therapeutic Drug Monitoring|December 17, 2009
High-resolution melting analysis of sequence variations in the cytidine deaminase gene (CDA) in patients with cancer treated with gemcitabineCaroline Raynal, Joseph Ciccolini, Cédric Mercier, et al.
Pageof 17